

**References for CEQUA® (cyclosporine ophthalmic solution) 0.09%
CEQUA Messaging Execution Guide / Resource Guide 2026**

References:

1. Hovanesian J, Berdy G, Sorensen R. CEQUA's Onset of Action Trial: an Investigation of Cyclosporine 0.09% Speed of Onset in Improving Ocular Surface Health in Dry Eye Patients. Presented at: ASCRS; April 25-28, 2025; Los Angeles, CA.
2. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. *Ophthalmology*. 2019;126(9):1230-1237.
3. CEQUA® prescribing information. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.
4. Malhotra R, Devries DK, Luchs J, et al. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b/3 and phase 3 studies. *Cornea*. 2019;38:1259-1265.
5. Johnston J, Adler R, Hessen M, et al. Effect of cyclosporine ophthalmic solution 0.09% on signs and symptoms of dry eye disease in patients inadequately controlled on cyclosporine ophthalmic emulsion 0.05%: results from a single-arm, open-label, phase 4 study. *Clin Ophthalmol* . 2026;20:583701.
6. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.
7. Weiss SL, Kramer WG. Ocular distribution of cyclosporine following topical administration of OTX-101 in New Zealand White rabbits. *J Ocul Pharmacol Ther*. 2019;35(7):395-402.
8. Mandal A, Bisht R, Rupenthal ID, Mitra A. Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies. *J Control Release*. 2017;248:96-116.
9. Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. *Transl Vis Sci Technol*. 2015;4(3):1-16.
10. US Patent 9,937,225 B2.
11. Karpecki P, Barghout V, Schenkel B, et al. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis. *BMC Ophthalmol*. 2023;23(1):443.

Current as of September 18, 2026

© 2026 Sun Pharmaceutical Industries, Inc. All rights reserved. CEQUA is a registered trademark of Sun Pharmaceutical Industries Limited. All other trademarks are the property of their respective owners.

PM-US-CQA-2280 09/2026